2019
Laboratory monitoring requirements during mycophenolate mofetil therapy for dermatologic conditions: A single-institution retrospective chart review
Waldman R, Strober B. Laboratory monitoring requirements during mycophenolate mofetil therapy for dermatologic conditions: A single-institution retrospective chart review. Journal Of The American Academy Of Dermatology 2019, 85: 726-728. PMID: 30797844, DOI: 10.1016/j.jaad.2019.02.040.Peer-Reviewed Original Research
2018
Methotrexate treatment of generalized granuloma annulare: a retrospective case series
Naka F, Strober B. Methotrexate treatment of generalized granuloma annulare: a retrospective case series. Journal Of Dermatological Treatment 2018, 29: 720-724. PMID: 29488435, DOI: 10.1080/09546634.2018.1447075.Peer-Reviewed Original ResearchConceptsGeneralized granuloma annulareRetrospective case seriesCase seriesMethotrexate treatmentGranuloma annulareAdverse effectsFirst-line therapyEfficacy of methotrexateMajority of patientsAvailable therapeutic modalitiesSmall case seriesIndividual case reportsLow internal validityDisease improvementInitial doseTreatment optionsCase reportComplete clearancePartial clearanceHair lossTherapeutic modalitiesPatientsSkin diseasesControl groupDisease severity
2016
Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series
Klufas D, Wald J, Strober B. Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. Pediatric Dermatology 2016, 33: 142-149. PMID: 26871417, DOI: 10.1111/pde.12782.Peer-Reviewed Original ResearchConceptsSevere pediatric psoriasisRetrospective case seriesPediatric psoriasisCase seriesSevere psoriasisSystemic therapySide effectsDisease responseSimilar side effect profilePhysician Global Assessment scaleComprehensive safety profileSmall sample sizeSingle referral centerSubjective side effectsSide effect profileSafety of treatmentMultiple treatment optionsAdverse event occurrenceComparison of efficacyGlobal Assessment ScalePaucity of dataAdult psoriasisImmunomodulating therapiesAdverse eventsReferral center
2008
Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis
Strober B, Teller C, Yamauchi P, Miller J, Hooper M, Yang Y, Dann F. Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis. British Journal Of Dermatology 2008, 159: 322-330. PMID: 18503600, DOI: 10.1111/j.1365-2133.2008.08628.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticBiomarkersBody Mass IndexC-Reactive ProteinDouble-Blind MethodEtanerceptFemaleHumansImmunoglobulin GMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRetrospective StudiesSeverity of Illness IndexTumor Necrosis Factor-alphaConceptsC-reactive proteinBody mass indexEffect of etanerceptCRP levelsPsoriatic arthritisCRP valuesBaseline C-reactive proteinC-reactive protein levelsHigher body mass indexLower body mass indexBaseline CRP valuesBaseline PASI scoreSkin disease activityStatin drug useSevere plaque psoriasisBaseline CRP levelsElevated CRP levelsSeverity Index scoreEtanercept treatmentRegistrational studiesCRP elevationPlaque psoriasisCardiovascular riskDisease activityPASI score